Brightgene Bio-Medical discovers new calcitonin/AMY3 receptor agonists

July 3, 2026

Brightgene Bio-Medical Technology Co. Ltd. has patented new calcitonin receptor (CALCR; CT-R) and amylin AMY3 receptor agonists potentially useful for the treatment of obesity and metabolic disorders.

BioWorld Science Endocrine/metabolic Patents

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Black wavy lines forming an abstract sound wave.png

Deep brain stimulation from the shallows: tomorrow’s BCI technology?

BioWorld

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...